Q32 Bio Statistics
Want to see QTTB full AI Analyst Report?
Q32 Bio (QTTB) Stock Statistics & Valuation Metrics
Total Valuation
Q32 Bio has a market cap or net worth of $263.93M. The enterprise value is -$3.10M.
- Market Cap
- $263.93M
- Enterprise Value
- -$3.10M
Share Statistics
Q32 Bio has 29,923,882 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 29,923,882
- Owned by Insiders
- 6.54%
- Owned by Institutions
- 22.63%
Financial Efficiency
Q32 Bio’s return on equity (ROE) is 0.71 and return on invested capital (ROIC) is 29.47%.
- Return on Equity (ROE)
- 0.71
- Return on Assets (ROA)
- 0.48
- Return on Invested Capital (ROIC)
- 29.47%
- Return on Capital Employed (ROCE)
- 0.34
- Revenue Per Employee
- 2.44M
- Profits Per Employee
- 1.36M
- Employee Count
- 22
- Asset Turnover
- 0.87
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Q32 Bio is 2.78. Q32 Bio’s PEG ratio is 0.01.
- PE Ratio
- 2.78
- PS Ratio
- 4.85
- PB Ratio
- 1.03
- Price to FCF
- -12.99
- Price to Operating Cash Flow
- -14.81
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Q32 Bio had revenue of 53.74M and earned 29.82M in profits. Earnings per share was 2.42.
- Revenue
- 53.74M
- Gross Profit
- 53.74M
- Operating Income
- 16.90M
- Pretax Income
- 29.82M
- Net Income
- 29.82M
- EBITDA
- 31.31M
- Earnings Per Share (EPS)
- 2.42
Cash Flow
In the last 12 months, operating cash flow was -20.02M and capital expenditures -52,000, giving a free cash flow of -20.07M billion.
- Operating Cash Flow
- -20.02M
- Free Cash Flow
- -20.07M
- Free Cash Flow per Share
- -0.59
Dividends & Yields
Q32 Bio pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.70%
- Earnings Yield
- 10.88%
Stock Price Statistics
- Beta
- 0.19
- 52-Week Price Change
- 294.12%
- 50-Day Moving Average
- 9.28
- 200-Day Moving Average
- 9.56
- Relative Strength Index (RSI)
- 44.59
- Average Volume (3m)
- 686.59K
Important Dates
Q32 Bio upcoming earnings date is Mar 16, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 04, 2026
- Next Earnings Date
- Mar 16, 2027
- Ex-Dividend Date
- ―
Financial Position
Q32 Bio as a current ratio of 4.85, with Debt / Equity ratio of 36.52%
- Current Ratio
- 4.85
- Quick Ratio
- 4.85
- Debt to Market Cap
- 0.25
- Net Debt to EBITDA
- -1.05
- Interest Coverage Ratio
- 15.37
Taxes
In the past 12 months, Q32 Bio has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Q32 Bio EV to EBITDA ratio is -0.73, with an EV/FCF ratio of 1.19.
- EV to Sales
- -0.44
- EV to EBITDA
- -0.73
- EV to Free Cash Flow
- 1.19
- EV to Operating Cash Flow
- 1.19
Balance Sheet
Q32 Bio has $289.59M in cash and marketable securities with $5.12M in debt, giving a net cash position of $284.46M billion.
- Cash & Marketable Securities
- $289.59M
- Total Debt
- $5.12M
- Net Cash
- $284.46M
- Net Cash Per Share
- $9.51
- Tangible Book Value Per Share
- $8.46
Margins
Gross margin is 99.84%, with operating margin of 34.20%, and net profit margin of 60.02%.
- Gross Margin
- 99.84%
- Operating Margin
- 34.20%
- Pretax Margin
- 60.02%
- Net Profit Margin
- 60.02%
- EBITDA Margin
- 60.83%
- EBIT Margin
- 60.18%
Analyst Forecast
The average price target for Q32 Bio is $39.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $39.43
- Price Target Upside
- 352.68% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- 55
